肿瘤I期剂量探索中联合模型的应用:频率学方法的考量
针对肿瘤I期剂量探索试验,本文提出一种纳入可预测后续临床毒性生物标志物的联合模型框架,并在多种剂量-毒性关系情景下与仅使用二分类毒性数据的似然型持续再评估方法(CRM)进行比较。模拟结果显示,联合模型通过整合生物标志物信息可缓解似然型CRM的估计问题并提高正确选择比例,但早期剂量探索研究固有的数据局限性在频率学框架下仍无法完全克服。
要点
- 联合模型纳入重复生物标志物测量可缓解小样本下似然型CRM的估计困难。
- 模拟显示联合模型提高正确选择比例,但早期数据局限性仍无法完全克服。
- 需重视似然型方法在I期剂量探索小样本场景中的估计挑战与恰当使用。
核心结论
- 联合模型框架通过整合生物标志物信息可缓解似然型CRM的估计问题并提高正确选择比例。
- 早期剂量探索研究固有的数据局限性在频率学框架下仍是无法完全克服的显著挑战。
研究设计与样本
- 方法学文章,提出纳入重复生物标志物测量的联合模型框架用于肿瘤I期剂量探索。
- 在多种剂量-毒性关系情景下,将联合模型与仅使用二分类毒性数据的似然型持续再评估方法(CRM)进行比较。
- 通过模拟研究评估方法性能。
主要发现
- 似然型方法在早期小样本剂量探索研究中存在此前被忽视的估计挑战。
- 模拟结果显示联合模型框架可缓解似然型CRM的估计问题。
- 联合模型框架可提高正确选择的比例。
- 早期剂量探索研究固有的数据局限性在频率学框架下无法完全克服。
临床怎么用
- 在肿瘤I期剂量探索中可考虑纳入预测后续临床毒性的生物标志物信息以辅助剂量选择。
- 使用似然型方法时应关注小样本下的估计挑战并恰当使用。
局限性
- 早期剂量探索研究固有的数据局限性在频率学框架下无法完全克服。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Dose-finding trials for oncology studies are traditionally designed to assess safety in the early stages of drug development. With the rise of molecularly targeted therapies and immuno-oncology compounds, biomarker-driven approaches are increasingly importance. In this article, we propose a novel approach to dose-finding that incorporates biomarkers which predict for the subsequent development of clinical toxicity. The proposed joint model framework, which incorporates repeated biomarker measurements, is compared to the likelihood-based continual reassessment method (CRM) using only binary toxicity data, across various dose-toxicity relationship scenarios. Our findings highlight a critical limitation of likelihood-based approaches in early-phase dose-finding studies with small sample sizes: estimation challenges that have been previously overlooked in the phase I dose-escalation setting. We explore potential remedies to address these challenges and emphasize the appropriate use of likelihood-based methods. Simulation results demonstrate that the proposed joint model framework, by integrating biomarker information, can alleviate estimation problems in the likelihood-based CRM and improve the proportion of correct selection. However, we highlight that the inherent data limitations in early phase dose-finding studies remain a significant challenge that cannot be fully overcome in the frequentist framework.
引用
- Chen X, Mozgunov P, Baird RD, et al. Using Joint Models in Phase I Dose-Finding Designs in Oncology: Considerations for Frequentist Approaches. Stat Med. 2026. PMID: 42866909. doi:10.1002/sim.70758
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。